Remus Pharmaceuticals Ltd.
NNSE:REMUS880.00
INR
-21.20
(-2.35%)
ISIN
INE0O5T01011
Return %
Stock
S&P 500
1Y
30.65
14.39
3Y
27.19
81.42
5Y
- -
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Arpit Deepakkumar Shah
- Full Time Employees
- 69
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1101 to 1103, Titanium One, Near Pakwan Cross Road, S.G. Highway Ahmedabad GU India 380054
- IPO Date
- May 29, 2023
- Website
- remuspharma.com
- Similar Companies
- Business
- Remus Pharmaceuticals Ltd. (REMUS.NS) is a pharmaceutical company specializing in the marketing, distribution, trading, and export of finished formulations, active pharmaceutical ingredients (APIs), and complex generics across key therapeutic areas including critical care, neurology, cardiology, diabetology, oncology, anti-infectives, dermatology, and immunology. The company offers a diverse portfolio exceeding 600 products in various dosage forms such as tablets, capsules, injections, powders for injections, ophthalmics, sachets, inhalers, semi-solids, large volume parenterals, oral solids, and oral liquids; specific categories encompass cardiovascular drugs (e.g., atorvastatin combinations, carvedilol), central nervous system agents (e.g., levetiracetam), antidiabetics, analgesics, antibacterials, antifungals, anti-cancer therapies (e.g., lenalidomide, olaparib), and contrast agents. It operates an asset-light model relying on loan licensing and contract manufacturing, with technical consultancy services, and targets institutional tenders, direct-to-consumer channels, and niche off-patent molecules for first-mover advantage in emerging markets. Incorporated in 2015 and headquartered in Ahmedabad, Gujarat, India, at 1101-1103, South Tower, One 42, Ambli-Bopal Road, the company conducts operations in over 20 countries across Latin America (e.g., Bolivia, Chile, Ecuador, Guatemala), Central America (e.g., Costa Rica, Dominican Republic, El Salvador, Honduras), the Caribbean (e.g., Jamaica, Trinidad and Tobago), Asia (e.g., Bhutan, Kuwait, Malaysia, Myanmar, Uzbekistan, Vietnam), Africa (e.g., Madagascar, Algeria), and the Middle East. Remus Pharmaceuticals maintains subsidiaries like Railas Pharma SRL in Bolivia for branded product commercialization in cardiovascular, hematology, neurology, and anti-infectives; it completed the acquisition of a 51% stake in Espee Biopharma & Finechem LLC in March 2024 and announced a new subsidiary for clinical trial research services in 2025. In 2023, the company transitioned from Remus Pharmaceuticals Private Limited to a public limited entity, listed on the NSE SME platform via an IPO in May 2023 raising approximately INR 47.69 crore, and issued a 1:1 bonus share in July 2025. Recent strategic expansions include entry into the Algerian market with product registrations, participation in Nicaragua national tenders securing key product awards, commercial launches of transdermal patches across multiple markets, and 37 new regulatory approvals in the Asian region as of Q2 FY2026; the company plans additional subsidiaries in three countries (e.g., Kenya, Chile, Dominican Republic) this fiscal year, with a shift toward B2C growth now comprising 13% of revenues. In 2021, it acquired injectable and oral solid formulation plants holding 23+ global accreditations for rest-of-world markets, building on 2017-2019 partnerships with multinational pharmaceuticals and 2022 strategic market entries. These initiatives support over 745 dossier registrations and participation in tenders for 20+ products per market, emphasizing affordable, high-quality generics for institutional and direct healthcare access.